TW202118518A - 用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法 - Google Patents

用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法 Download PDF

Info

Publication number
TW202118518A
TW202118518A TW109125563A TW109125563A TW202118518A TW 202118518 A TW202118518 A TW 202118518A TW 109125563 A TW109125563 A TW 109125563A TW 109125563 A TW109125563 A TW 109125563A TW 202118518 A TW202118518 A TW 202118518A
Authority
TW
Taiwan
Prior art keywords
tumor
cancer
conjugate
antibody
cells
Prior art date
Application number
TW109125563A
Other languages
English (en)
Chinese (zh)
Inventor
古茲曼 馬吉爾 蓋西亞
羅傑 荷姆
俊翎 方
Original Assignee
美商樂天醫藥生技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商樂天醫藥生技股份有限公司 filed Critical 美商樂天醫藥生技股份有限公司
Publication of TW202118518A publication Critical patent/TW202118518A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW109125563A 2019-07-30 2020-07-29 用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法 TW202118518A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962880514P 2019-07-30 2019-07-30
US62/880,514 2019-07-30
US201962896453P 2019-09-05 2019-09-05
US62/896,453 2019-09-05
US201962931405P 2019-11-06 2019-11-06
US62/931,405 2019-11-06

Publications (1)

Publication Number Publication Date
TW202118518A true TW202118518A (zh) 2021-05-16

Family

ID=72047165

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109125563A TW202118518A (zh) 2019-07-30 2020-07-29 用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法

Country Status (6)

Country Link
US (1) US20220313822A1 (https=)
EP (1) EP4004048A1 (https=)
JP (1) JP7627259B2 (https=)
CN (1) CN114423453A (https=)
TW (1) TW202118518A (https=)
WO (1) WO2021021882A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564879A (zh) 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
AU2016308286B2 (en) 2015-08-18 2022-04-07 Rakuten Medical, Inc. Phthalocyanine dye conjugates and their storage
TW202133886A (zh) * 2019-12-06 2021-09-16 美商樂天醫藥生技股份有限公司 用於增強免疫及腫瘤治療之方法
WO2022182483A1 (en) * 2021-02-02 2022-09-01 Rakuten Medical, Inc. Methods for local and systemic treatment of cancers, tumors and tumor cells
CA3260932A1 (en) * 2022-06-30 2024-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services CD25-SPECIFIC ANTIBODIES AND THEIR USES
EP4662238A1 (en) * 2023-02-06 2025-12-17 F. Hoffmann-La Roche AG Combination therapy and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103781495A (zh) * 2011-07-11 2014-05-07 美国政府(由卫生和人类服务部的部长所代表) 光敏抗体-荧光团缀合物
SG11201610052TA (en) * 2014-08-08 2017-02-27 Us Health Photo-controlled removal of targets in vitro and in vivo
CN108137701A (zh) * 2015-08-07 2018-06-08 美国政府(由卫生和人类服务部的部长所代表) 用于治疗癌症的针对抑制细胞的近红外光免疫疗法(nir-pit)
CN119564879A (zh) * 2015-08-18 2025-03-07 乐天医药生技股份有限公司 用于光免疫疗法的组合物、联用及相关方法
RU2740793C2 (ru) 2016-10-25 2021-01-21 Ракутен Медикал, Инк. Светорассеивающие устройства для использования в фотоиммунотерапии
US10416366B2 (en) 2016-10-25 2019-09-17 Rakuten Medical, Inc. Light diffusing devices for use in photoimmunotherapy
US11685782B2 (en) * 2017-10-23 2023-06-27 Children's Medical Center Corporation Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
CA3096305A1 (en) * 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation

Also Published As

Publication number Publication date
CN114423453A (zh) 2022-04-29
WO2021021882A1 (en) 2021-02-04
JP7627259B2 (ja) 2025-02-05
US20220313822A1 (en) 2022-10-06
JP2022543765A (ja) 2022-10-14
EP4004048A1 (en) 2022-06-01

Similar Documents

Publication Publication Date Title
TW202118518A (zh) 用於癌症、腫瘤及腫瘤細胞之局部及全身性治療之組合物及方法
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
CN111936164B (zh) 癌的治疗和/或预防用药物组合物
US9132281B2 (en) Focused radiation for augmenting immune-based therapies against neoplasms
ES2563439T5 (es) Medios y métodos para tratar LDCBG
JP7579705B2 (ja) アンタゴニスト抗ｐｄ－１抗体による癌の治療方法
US20240307541A1 (en) Methods for local and systemic treatment of cancers, tumors and tumor cells
AU2018225177A1 (en) Therapeutic compositions and related methods for photoimmunotherapy
JP7473474B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
WO2019072220A1 (zh) Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途
TW202133886A (zh) 用於增強免疫及腫瘤治療之方法
KR20080091427A (ko) 동시 화학요법 및 면역요법
CN111166878B (zh) 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途
TW202116353A (zh) 使用酞菁染料靶向分子結合物之治療方法
WO2021182571A1 (ja) 癌の治療及び／又は予防のための医薬品
US20220105182A1 (en) Radiotherapy improvements
US20200297741A1 (en) Compounds, composition and uses thereof for treating cancer
WO2021182572A1 (ja) 癌の治療及び／又は予防のための医薬品
WO2026052074A1 (zh) 包含抗体偶联药物和免疫检查点抑制剂的药物组合及其应用
CN108368485A (zh) 具有抗趋除特性的修饰的天然杀伤细胞及其用途
HK40092801A (zh) 用於治疗癌症的纳米颗粒组合物